AI Prospecting for SEEL
Company data:
Company size:
131 employeesWebsite URL:
https://www.seelos.comIndustry
BiotechnologyHeadquarters:
300 Park Avenue, 12th Floor, New York, NY, USAInvestment round:
Publicly Traded (NASDAQ: SEEL)ARR:
N/AKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about SEEL
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
There is no recent significant news available for "SEEL" (Seelos Therapeutics) in the provided sources. To find the latest news, you would need to check the company's official website, recent press releases, or financial news outlets.
Seelos Therapeutics, Inc. filed for bankruptcy on November 15, 2023, and was delisted from Nasdaq. The company had been involved in various clinical trials, including the development of SLS-002 for acute suicidal ideation and behavior, and SLS-005 for amyotrophic lateral sclerosis and other conditions[2][4][5].
Seelos Therapeutics filed for Chapter 11 bankruptcy on November 15, 2024, with the US Bankruptcy Court for the Southern District of New York, citing assets of less than $0.05 million and liabilities between $10 million to $50 million. The company's stock transitioned to the OTC Pink Market on November 19, 2024, due to the bankruptcy filing[2][5].
Open job positions at SEEL
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
